VIP — Peptide Dosing Protocols reference

The FDA declined an emergency use authorization.

There is currently no established FDA-approved subcutaneous VIP dosing protocol.

This is not a dosing recommendation Do not treat SubQ VIP like a casual supplement.

VIP Peptide Dosing Guide: Vasoactive Intestinal Peptide Protocol (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols VIP Peptide Dosing Guide: Vasoactive Intestinal Peptide Protocol (2026) Protocol / Research Dosing Guide VIP Peptide Dosing Guide: Vasoactive Intestinal Peptide Protocol (2026) This VIP peptide guide explains the main SubQ research dosing ranges, how to reconstitute a 10 mg vial with 3 mL BAC water, what to monitor, and how nasal-spray protocols differ from injectable VIP.

By Garret Grant · Founder & Lead Researcher · Last reviewed Jun 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Link Verified Supplier Link Peptide Partners VIP Peptide Supply View Supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart How It Works Who Should Avoid Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Comparisons Related Stacking Protocols FAQ References VIP Peptide Quick Start VIP stands for vasoactive intestinal peptide .

It is a natural signaling molecule (a neuropeptide) made of 28 amino acids.

This page focuses on the nasal and subcutaneous research formats and explains the others for context.

Common formats Compounded intranasal spray (about 50 mcg per spray) or a subcutaneous research vial (often 10 mg).

Safety gate Lipase, a pancreas blood marker, is checked before and during use.

Reconstitution A 10 mg subcutaneous vial with 3 mL bacteriostatic water gives about 3.33 mg/mL.

Research status Not FDA-approved as a standalone drug.

VIP is not FDA-approved as a standalone drug, and both injectable and intranasal use should be discussed with a qualified clinician before any use.

VIP Peptide Dosing Protocol & Schedule VIP dosing changes by route.

VIP Dosing Guide by Route Start here for SubQ research-vial dosing.

SubQ (Injection) Intranasal (Nasal Spray) The research-vial format behind most subcutaneous VIP protocols.

They are not FDA-approve

d dosing instructions.

VIP (Vasoactive Intestinal Peptide) Research Dosing Protocol Phase Conservative Start Dose 50 mcg Frequency Once daily Route SubQ Duration 1-2 weeks Phase Standard Research Dose Dose 100 mcg Frequency 1-2x daily Route SubQ Duration Ongoing Phase Advanced Research Dose Dose 200 mcg Frequency 1-2x daily Route SubQ Duration Ongoing Phase Clinic-Style Protocol Dose 200 mcg Frequency 5x weekly Route SubQ Duration Ongoing Phase Dose Frequency Route Duration Conservative Start 50 mcg Once daily SubQ 1-2 weeks Standard Research Dose 100 mcg 1-2x daily SubQ Ongoing Advanced Research Dose 200 mcg 1-2x daily SubQ Ongoing Clinic-Style Protocol 200 mcg 5x weekly SubQ Ongoing VIP Cycling Guidance Parameter Loading Phase Recommendation Not typically used Parameter Cycling Recommendation No standardized cycling protocol Parameter Common Approach Recommendation Continuous administration Parameter Maintenance Recommendation Lowest effective dose after response Parameter Washout Period Recommendation Not established in literature Parameter Recommendation Loading Phase Not typically used Cycling No standardized cycling protocol Common Approach Continuous administration Maintenance Lowest effective dose after response Washout Period Not established in literature Community-reported dosing most commonly falls between 50-200 mcg per injection .

100 mcg tw

VIP has a very short biological half-life, which is why divided daily dosing is common.

In the published clinic protocol associated with mold-illness (CIRS) work, the reported structure is 50 mcg per spray , often 4 to 8 sprays per day in alternating nostrils.

Some severe cases reported higher daily totals under stricter monitoring.

This is not a dosing recommendation.

A key detail from that protocol: the first dose is given in a clinic , with lipase and other labs checked before and shortly after, to watch for a pancreatic reaction.

This is not a dosing recommendation The intranasal figures describe a clinician-supervised protocol with mandatory lab monitoring.

VIP Peptide Supplies Needed The supply math below uses the high-end SubQ example from the dosing table: 200 mcg, five days per week, from a 10 mg vial mixed with 3 mL BAC water.

At that concentration, one vial provides about 50 high-end doses.

Lower 50-100 mcg doses last longer.

Peptide Vials Each 10 mg vial reconstituted with 3 mL BAC water provides about 50 doses of 200 mcg, 100 doses of 100 mcg, or 200 doses of 50 mcg.

Cycle length Planning note 4-8 weeks 1 vial 4 weeks: 20 high-end doses needed; one vial covers ~50.; 6 weeks: 30 high-end doses needed.; 8 weeks: 40 high-end doses needed.

12 weeks 2 vials 60 high-end doses needed; one vial covers ~50.

4-8 weeks 1 vial 4 weeks: 20 high-end doses needed; one vial covers ~50.; 6 weeks: 30 high-end doses needed.; 8 weeks: 40 high-end doses needed.

high-end doses needed; one vial covers ~50.

Insulin Syringes (U-100) One syringe per injection; 0.3 mL / 30-unit barrels suit 1.5-6 unit draws.

Cycle length Planning note 4 weeks 20 syringes 5 per week 6 weeks 30 syringes 5 per week 8 weeks 40 syringes 5 per week 12 weeks 60 syringes 5 per week 4 weeks 20 syringes 5 per week 6 weeks 30 syringes 5 per week 8 weeks 40 syringes 5 per week 12 weeks 60 syringes 5 per week Bacteriostatic Water Use 3 mL per 10 mg vial for reconstitution.

Cycle length Planning note 4-12 weeks 1 x 10 mL bottle 4 weeks: 1 vial uses 3 mL; 6 weeks: 1 vial uses 3 mL; 8 weeks: 1 vial uses 3 mL; 12 weeks: 2 vials use 6 mL 4-12 weeks 1 x 10 mL bottle 4 weeks: 1 vial uses 3 mL; 6 weeks: 1 vial uses 3 mL; 8 weeks: 1 vial uses 3 mL; 12 weeks: 2 vials use 6 mL Round up for priming losses, dropped syringes, and damaged swabs.

VIP Peptide Reconstitution Guide Reconstitution applies to the subcutaneous research vial , not the nasal spray (which arrives already prepared).

The example below uses a 10 mg lyophilized vial mixed with 3 mL bacteriostatic water.

COVID / lung failure (aviptadil) — negative The definitive NIH trial (ACTIV-3b / TESICO) found that IV aviptadil did NOT significantly improve outcomes through day 90 versus placebo.

Reconstitution Math (10 mg vial, 3 mL BAC water) BAC water added 3.0 mL Concentration 3.33 mg/mL 50 mcg 0.015 mL / 1.5 units 100 mcg 0.030 mL / 3 units 200 mcg 0.060 mL / 6 units BAC water added Concentration 50 mcg 100 mcg 200 mcg 3.0 mL 3.33 mg/mL 0.0